
Israel generics giant Teva Pharmaceutical Industries (NYSE: TEVA) has entered into a definitive agreement to acquire US privately-held biotech firm Labrys Biologicals, which is focused on treatments for chronic migraine and episodic migraine, broadening Teva’s array of biotechnology assets and capabilities.
Teva will acquire Labrys for $200 million upfront in cash at closing as well as up to $625 million in contingent payments on achievement of certain pre-launch milestones. Potential peak sales for LBR-101, a chronic and episodic migraine treatment candidate now in Phase IIb testing, are estimated to reach between $2 billion and $3 billion. The closing of this transaction is subject to antitrust clearance and satisfaction of other conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze